Compounding lobby group sues FDA over semaglutide shortage list removal, arguing Novo Nordisk's Ozempic and Wegovy remain in ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

An Illinois jury ruled in favor of Boehringer Ingelheim in Zantac litigation brought by two prostate cancer patients, the ...

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...

Duality Biologics, an ADC startup that's attracted multiple biopharma partnerships, has let its plans to list on the Hong Kong Stock Exchange fizzle out.

Thermo Fisher Scientific is spending $4.1 billion in cash to acquire US healthcare company Solventum’s purification and ...

Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...

Repare Therapeutics cuts 75% of workforce and CMO Maria Koehler departs amid program pause. Multiple companies announce layoffs, funding deals, and trial updates.

FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...

Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it ...

Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...

For the fourth year running, Endpoints News will highlight the biotech leaders who are paving the way for the LGBTQ+ ...